Cancer patients with COVID: do early antiviral drugs help?

NCT ID NCT07241975

Completed Knowledge-focused Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study looked at how well early COVID-19 antiviral therapies work in cancer patients. Researchers tracked 112 patients with solid tumors who received these treatments to see how many needed hospitalization within 14 days. The goal is to fill knowledge gaps and improve care for this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: early antiviral therapies for COVID-19
What this could lead to: If successful, this study could help doctors choose the best COVID-19 treatments for cancer patients, potentially reducing hospitalizations and deaths.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It is also small (112 patients) and focused on one hospital, so findings may not apply to all cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER PATIENTS IN TREATMENT ACTIVE WHO RECEIVE EARLY OUT-PATIENT THERAPY AGAINST SARS-COV-2

Contacts and locations

Locations

Fondazione IRCCS Policlinico San Matteo, SC Oncologia

Pavia, Pavia, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.